News

BlogsPosts
Press Release
RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
VANCOUVER, BC – June 20, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF),
BlogsPosts
Press Release
RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement
VANCOUVER, BC – June 17, 2014 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”)
BlogsPosts
Press Release
RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant
VANCOUVER, BC – June 5, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF),
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of Second Tranche of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES ORDISSEMINATION IN OR INTO THE UNITED STATES
BlogsPosts
Press Release
RepliCel Life Sciences’ Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
VANCOUVER, BC – May 20, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
RepliCel Life Sciences Inc. Announces Closing of Brokered and Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES WIRE SERVICES ORDISSEMINATION IN OR INTO THE UNITED STATES
BlogsPosts
Press Release
RepliCel Life Sciences Announces Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS
BlogsPosts
Press Release
RepliCel Reports 2013 Annual Financial Results
VANCOUVER, BC – March 18, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
RepliCel Retains Ubika Communication for Online Capital Market Exposure
VANCOUVER, BC – February 26, 2014 – RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF),
BlogsPosts
Press Release
RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
VANCOUVER, BC – January 13, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP)
BlogsPosts
Press Release
RepliCel to Commence Trading on the TSX Venture Exchange
VANCOUVER, BC – January 9, 2014 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CSE: RP)
BlogsPosts
Press Release
RepliCel Announces Conditional Approval from TSX Venture Exchange
VANCOUVER, BC – January 2, 2014 –RepliCel Life Sciences Inc. (the “Company” or “RepliCel”) (OTCQB:
BlogsPosts
Press Release
RepliCel Reports Progress on Shiseido Technology Transfer for RCH-01 Treatment for Pattern Baldness
VANCOUVER, BC – December 19, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP)
BlogsPosts
Press Release
RepliCel Reports Third Quarter 2013 Financial Results and Provides Corporate Update
VANCOUVER, BC – November 20, 2013 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (CNSX: RP),
BlogsPosts
Press Release
RepliCel Forms Clinical Advisory Board to Support the Development of RCT-01 for the Treatment of Chronic Tendinosis
VANCOUVER, BC – October 30, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP),
BlogsPosts
Press Release
RepliCel Announces Stock Option Grant
VANCOUVER, BC – September 6, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP),
BlogsPosts
Press Release
RepliCel Retains Westwicke Partners as Investor Relations Counsel
VANCOUVER, BC – September 4, 2013 – RepliCel Life Sciences Inc. (OTCBB: REPCF) (CNSX: RP),
BlogsPosts
Press Release
RepliCel Announces Closing of Private Placement
VANCOUVER, BC – April 10, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)
BlogsPosts
Press Release
Replicel and Shiseido Complete Collaboration and Technology Transfer Agreement on Technology for Treating Pattern Baldness
VANCOUVER, BC – July 11, 2013 – RepliCel Life Sciences Inc. (the “Company” or “RepliCel”)
BlogsPosts
Press Release
RepliCel and Shiseido Announce Collaboration and Technology Transfer Framework Agreement and Exclusive Geographic Technology License
Tokyo, Japan and Vancouver, Canada – May 29, 2013 – RepliCel Life Sciences Inc. (the

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.